{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:58:43Z","timestamp":1787986723216,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Affimed GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41375-021-01478-w","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:02:56Z","timestamp":1641772976000},"page":"1006-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A BCMA\/CD16A bispecific innate cell engager for the treatment of multiple myeloma"],"prefix":"10.1038","volume":"36","author":[{"given":"Satoko","family":"Kakiuchi-Kiyota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi Ackerly","family":"Wallweber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Schutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-1990","authenticated-orcid":false,"given":"Adeyemi O.","family":"Adedeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-085X","authenticated-orcid":false,"given":"Hao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srividya","family":"Myneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Fullerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Corr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"de Almeida Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiko","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Meric","family":"Ovacik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Wingert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Rajkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ellwanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3289-6502","authenticated-orcid":false,"given":"Andrew G.","family":"Polson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"1478_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cpt.550","volume":"101","author":"JP Laubach","year":"2017","unstructured":"Laubach JP, Paba Prada CE, Richardson PG, Longo DL. Daratumumab, elotuzumab, and the development of therapeutic monoclonal antibodies in multiple myeloma. Clin Pharm Ther. 2017;101:81\u20138.","journal-title":"Clin Pharm Ther"},{"key":"1478_CR2","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487\u201398.","journal-title":"N Engl J Med"},{"key":"1478_CR3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906\u201317.","journal-title":"N Engl J Med"},{"key":"1478_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","volume":"19","author":"YT Tai","year":"2019","unstructured":"Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019;19:1143\u201356.","journal-title":"Expert Opin Biol Ther"},{"key":"1478_CR5","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"SF Cho","year":"2018","unstructured":"Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.","journal-title":"Front Immunol"},{"key":"1478_CR6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","volume":"5","author":"DJ DiLillo","year":"2021","unstructured":"DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021;5:1291\u2013304.","journal-title":"Blood Adv"},{"key":"1478_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38:775\u201383.","journal-title":"J Clin Oncol"},{"key":"1478_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ph14010040","volume":"14","author":"G Baril\u00e0","year":"2021","unstructured":"Baril\u00e0 G, Rizzi R, Zambello R, Musto P. Drug conjugated and bispecific antibodies for multiple myeloma: improving immunotherapies off the shelf. Pharmaceuticals. 2021;14:40.","journal-title":"Pharmaceuticals"},{"key":"1478_CR9","doi-asserted-by":"publisher","first-page":"620312","DOI":"10.3389\/fimmu.2020.620312","volume":"11","author":"X Zhou","year":"2020","unstructured":"Zhou X, Rasche L, Kort\u00fcm KM, Danhof S, Hudecek M, Einsele H. Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies. Front Immunol. 2020;11:620312.","journal-title":"Front Immunol"},{"key":"1478_CR10","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2019004701","volume":"136","author":"NL Bartlett","year":"2020","unstructured":"Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136:2401\u20139.","journal-title":"Blood."},{"key":"1478_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/mt.2013.14","volume":"21","author":"KS Reiners","year":"2013","unstructured":"Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, et al. Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013;21:895\u2013903.","journal-title":"Mol Ther"},{"key":"1478_CR12","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:4024\u201331.","journal-title":"Blood."},{"key":"1478_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.4161\/mabs.28591","volume":"6","author":"U Reusch","year":"2014","unstructured":"Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, et al. A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells. MAbs. 2014;6:727\u201338.","journal-title":"MAbs."},{"key":"1478_CR14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","volume":"99","author":"G Cartron","year":"2002","unstructured":"Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754\u20138.","journal-title":"Blood."},{"key":"1478_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","volume":"26","author":"A Musolino","year":"2008","unstructured":"Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26:1789\u201396.","journal-title":"J Clin Oncol"},{"key":"1478_CR16","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1:2105\u201314.","journal-title":"Blood Adv"},{"key":"1478_CR17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/19420862.2019.1616506","volume":"11","author":"K Ellwanger","year":"2019","unstructured":"Ellwanger K, Reusch U, Fucek I, Wingert S, Ross T, M\u00fcller T, et al. Redirected optimized cell killing (ROCK\u00ae): a highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. MAbs. 2019;11:899\u2013918.","journal-title":"MAbs."},{"key":"1478_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/cyto.b.21590","volume":"94","author":"E Alaterre","year":"2018","unstructured":"Alaterre E, Raimbault S, Garcia JM, R\u00e8me T, Requirand G, Klein B, et al. Automated and simplified identification of normal and abnormal plasma cells in multiple myeloma by flow cytometry. Cytom B Clin Cytom. 2018;94:484\u201392.","journal-title":"Cytom B Clin Cytom"},{"key":"1478_CR19","unstructured":"Kay B, Winter J, McCafferty J. Phage display of peptides and proteins. San Diego, CA, USA: Academic Press; 1996."},{"key":"1478_CR20","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-04-2263","volume":"11","author":"R Niwa","year":"2005","unstructured":"Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005;11:2327\u201336.","journal-title":"Clin Cancer Res"},{"key":"1478_CR21","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1084\/jem.180.4.1395","volume":"180","author":"WE Carson","year":"1994","unstructured":"Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395\u2013403.","journal-title":"J Exp Med"},{"key":"1478_CR22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","volume":"90","author":"HR Koene","year":"1997","unstructured":"Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype. Blood. 1997;90:1109\u201314.","journal-title":"Blood."},{"key":"1478_CR23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1172\/JCI119616","volume":"100","author":"J Wu","year":"1997","unstructured":"Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Investig. 1997;100:1059\u201370.","journal-title":"J Clin Investig"},{"key":"1478_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21\u201333.","journal-title":"Mayo Clin Proc"},{"key":"1478_CR25","doi-asserted-by":"publisher","first-page":"16727","DOI":"10.1074\/jbc.M312316200","volume":"279","author":"DR Patel","year":"2004","unstructured":"Patel DR, Wallweber HJA, Yin J, Shriver SK, Marsters SA, Gordon NC, et al. Engineering an APRIL-specific B cell maturation antigen. J Biol Chem. 2004;279:16727\u201335.","journal-title":"J Biol Chem"},{"key":"1478_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","volume":"81","author":"H Chen","year":"2019","unstructured":"Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 2019;81:62\u20136.","journal-title":"Leuk Res"},{"key":"1478_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","volume":"102","author":"M Ghermezi","year":"2017","unstructured":"Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102:785\u201395.","journal-title":"Haematologica."},{"key":"1478_CR28","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641\u201353.","journal-title":"Lancet Oncol"},{"key":"1478_CR29","doi-asserted-by":"crossref","first-page":"LB-299","DOI":"10.1158\/1538-7445.AM2018-LB-299","volume":"78","author":"A Goyos","year":"2018","unstructured":"Goyos A, Li C-M, Deegen P, Bogner P, Thomas O, Wahl J, et al. Abstract LB-299: Cynomolgus monkey plasma cell gene signature to quantify thein vivoactivity of a half-life extended anti-BCMA BiTE\u00ae for the treatment of multiple myeloma. Cancer Res. 2018;78:LB-299.","journal-title":"Cancer Res"},{"key":"1478_CR30","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.4049\/jimmunol.1400531","volume":"193","author":"CD Castro","year":"2014","unstructured":"Castro CD, Flajnik MF. Putting J chain back on the map: how might its expression define plasma cell development? J Immunol. 2014;193:3248\u201355.","journal-title":"J Immunol"},{"key":"1478_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/bjh.15122","volume":"184","author":"N van de Donk","year":"2019","unstructured":"van de Donk N, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, et al. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed\/refractory multiple myeloma. Br J Haematol. 2019;184:475\u20139.","journal-title":"Br J Haematol"},{"key":"1478_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/bjc.1998.518","volume":"78","author":"MP Velders","year":"1998","unstructured":"Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer. 1998;78:478\u201383.","journal-title":"Br J Cancer"},{"key":"1478_CR33","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang Y, Hughes T, Zhang J, Caligiuri MA, Benson DM, et al. Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells. Clin Cancer Res. 2018;24:4006\u201317.","journal-title":"Clin Cancer Res"},{"key":"1478_CR34","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s40265-018-0969-4","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN. Elotuzumab: a review in relapsed and\/or refractory multiple myeloma. Drugs. 2018;78:1481\u20138.","journal-title":"Drugs."},{"key":"1478_CR35","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3389\/fimmu.2018.01228","volume":"9","author":"T Plesner","year":"2018","unstructured":"Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma. Front Immunol. 2018;9:1228.","journal-title":"Front Immunol"},{"key":"1478_CR36","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/JLB.2RU0517-176RR","volume":"103","author":"P Liu","year":"2018","unstructured":"Liu P, Jin Y, Sattar H, Liu H, Xie W, Zhou F. Natural killer cell immunotherapy against multiple myeloma: progress and possibilities. J Leukoc Biol. 2018;103:821\u20138.","journal-title":"J Leukoc Biol"},{"key":"1478_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/cancers11010085","volume":"11","author":"JI Luna","year":"2019","unstructured":"Luna JI, Grossenbacher SK, Sturgill IR, Ames E, Judge SJ, Bouzid LA, et al. Bortezomib augments natural killer cell targeting of stem-like tumor cells. Cancers. 2019;11:85.","journal-title":"Cancers"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01478-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01478-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01478-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T10:11:43Z","timestamp":1674382303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01478-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1478"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01478-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"5 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK-K, HAW, JRK, MMS, AOA, JinL, HC, RH, LL, AF, NC, LY, DdeAN, SZ, SRL, JiL, RN, TS, AMO, BZ, MD, CS, SC, SM and AGP are employees of Genentech and TR, SW, ER, KE and UR are employees of Affimed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}